TRLV · NYSE · CIK 0001754195
Trulieve Cannabis Corp.
Trulieve Cannabis Corp.’s most recent SEC filing in our snapshot is a Form S-8 POS filed on Aug 24, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $1.2B and net income of -$122.2M, according to its XBRL data on EDGAR. Its EDGAR record lists 26 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- Trulieve Cannabis Corp.
- Ticker
- TRLV
- SEC Central Index Key (CIK)
- 0001754195
- Industry (SIC)
- Medicinal Chemicals & Botanical Products (code 2833)
- Business address
- TALLAHASSEE, FL
- State or country of incorporation
- British Columbia, Canada
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #1928 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from Trulieve Cannabis Corp.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $931.9M | $1.2B | $1.1B | $1.2B | $1.2B |
| Net income | $17.4M | -$252.7M | -$533.1M | -$160.6M | -$122.2M |
| Diluted EPS | $0.21 | -$0.95 | -$2.28 | -$0.79 | -$0.58 |
| Total assets | $3.4B | $3.4B | $2.7B | $2.9B | $2.7B |
| Cash and equivalents | $226.6M | $207.2M | $201.4M | $238.8M | $255.5M |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Feb 26, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 7, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 11, 2026 | 8-K | Material agreement; Unregistered equity sale; Change to shareholder rights; Charter, bylaws or fiscal year change· period Aug 11, 2026 | Document · Index |
| Jun 25, 2026 | DEF 14A | Definitive proxy statement· period Jun 25, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about Trulieve Cannabis Corp., by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Aug 24, 2026 | S-8 POS | S-8 POS | Document · Index |
| Aug 24, 2026 | POSASR | POSASR | Document · Index |
| Aug 11, 2026 | 8-K | Material agreement; Unregistered equity sale; Change to shareholder rights; Charter, bylaws or fiscal year change· period Aug 11, 2026 | Document · Index |
| Aug 7, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 7, 2026 | 8-K | Acquisition or disposition completed; Regulation FD disclosure· period Aug 7, 2026 | Document · Index |
| Aug 5, 2026 | 8-K | Shareholder vote results· period Aug 5, 2026 | Document · Index |
| Jul 8, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Jul 2, 2026 | 8-K | Director or officer change· period Jun 30, 2026 | Document · Index |
| Jun 26, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 26, 2026 | Document · Index |
| Jun 25, 2026 | DEFA14A | Additional proxy soliciting materials | Document · Index |
| Jun 25, 2026 | DEF 14A | Definitive proxy statement· period Jun 25, 2026 | Document · Index |
| Jun 25, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 23, 2026 | Document · Index |
| Jun 22, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 17, 2026 | Document · Index |
| Jun 17, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Jun 12, 2026 | PRE 14A | PRE 14A· period Jun 8, 2026 | Document · Index |
| Jun 12, 2026 | 8-K | Director or officer change· period Jun 11, 2026 | Document · Index |
| Jun 11, 2026 | 8-K | Shareholder vote results· period Jun 9, 2026 | Document · Index |
| Jun 9, 2026 | 8-K | Other events· period Jun 9, 2026 | Document · Index |
| Jun 9, 2026 | 8-A12B | 8-A12B | Document · Index |
| Jun 9, 2026 | CERT | NYSE CERTIFICATION | Document · Index |
| Jun 4, 2026 | 8-K | Material agreement; Acquisition or disposition completed· period Jun 3, 2026 | Document · Index |
| May 7, 2026 | 10-Q | Quarterly report· period Mar 31, 2026 | Document · Index |
| May 7, 2026 | 8-K | Results of operations; Regulation FD disclosure· period May 7, 2026 | Document · Index |
| Apr 29, 2026 | DEFA14A | Additional proxy soliciting materials | Document · Index |
| Apr 29, 2026 | ARS | ARS· period Dec 31, 2025 | Document · Index |
| Apr 29, 2026 | DEF 14A | Definitive proxy statement· period Dec 31, 2025 | Document · Index |
| Apr 21, 2026 | 8-K | Director or officer change· period Apr 15, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 3, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026 | Document · Index |
Insider filing activity
26 Form 4 filings appear in Trulieve Cannabis Corp.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Medicinal Chemicals & Botanical Products
- RGC Regencell Bioscience Holdings Ltd
- DFTX Definium Therapeutics, Inc.
- CURLF Curaleaf Holdings, Inc.
- CRON Cronos Group Inc.
- RAJAF TFA Therapeutics, Inc.
All 6 companies in Medicinal Chemicals & Botanical Products· Companies headquartered in Florida
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001754195 and XBRL company facts. Trulieve Cannabis Corp. on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement